Trials / Sponsors / Samus Therapeutics, Inc.
Samus Therapeutics, Inc.
Industry · 8 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | 2023-01-01 |
| Withdrawn | A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN Accelerated Phase MPN, Blast Phase MPN | Phase 2 | 2022-06-15 |
| Terminated | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma | Phase 1 | 2021-12-27 |
| Terminated | To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia Alzheimer Disease | Phase 2 | 2020-06-30 |
| Terminated | Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) | Phase 1 | 2019-08-12 |
| Terminated | A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Sub Alzheimer's Disease | Phase 1 | 2019-06-24 |
| Terminated | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | 2018-05-24 |
| Terminated | PET Imaging of Subjects Using 124I-PU-AD Lymphoma, Solid Malignancy, Alzheimer Disease | EARLY_Phase 1 | 2016-04-01 |